AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31189238
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment combined with TCM syndrome differentiation
Trial: 18289334
Drug: Azithromycin 500
RxNorm normalized name: azithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 500 mg thrice weekly (on Monday, Wednesday, and Saturday) for the first month, 250 mg thrice weekly for the second month, and 250 mg twice weekly for the third month.
Trial: 18289334
Drug: Doxycycline 100
RxNorm normalized name: doxycycline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline 100 mg/day for three months.
Trial: 8179541
Drug: Terbutaline (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline (0.25 mg subcutaneously)
Trial: 30668243
Drug: CRP plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRP plus 8.5% doxycycline hyclate gel
Trial: 30668243
Drug: CRP plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRP plus 2% clindamycin hydrochloride gel
Trial: 29776987
Drug: 150-μg subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150-μg subcutaneous glucagon (MDG)
Trial: 29776987
Drug: 50% basal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50% basal insulin reduction
Trial: 29776987
Drug: 40-g oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40-g oral glucose tablets
Trial: 26610183
Drug: Radial shock
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radial shock wave therapy (rESWT) with nightly splinting
Trial: 19195847
Drug: Oral antipsychotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antipsychotics (AP)
Trial: 11152919
Drug: 0.625 mg
RxNorm normalized name: estrone 0.625 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg of conjugated estrogens plus 2.5 mg of medroxyprogesterone acetate in one tablet daily (n = 768)
Trial: 18219129
Drug: IVIg treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIg treatment guided by RT‐PCR
Trial: 523424
Drug: Cholintheophyllinate (Euspirax)
RxNorm normalized name: chlortheophylline
DrugBank: 8-chlorotheophylline (DB14132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholintheophyllinate (Euspirax) 400 mg
Trial: 523424
Drug: Theophyllin‐Aethylendiamine (Euphyllin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophyllin‐Aethylendiamine (Euphyllin retard) 350 mg
Trial: 26975890
Drug: Standard oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oxygen therapy (up to 15 L/min to maintain SpO2 of 94% or higher) (n=145)
Trial: 23964144
Drug: 45 mL
RxNorm normalized name: ethanol 0.645 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45 mL of NaP + 20 mg of bisacodyl (prep 2)
Trial: 23964144
Drug: 4 L
RxNorm normalized name: PEG-4 laurate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 L of PEG (prep 3)
Trial: 23964144
Drug: NaP preparations
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaP preparations (comparing all NaP preparations to PEG preparations)
Trial: 20466530
Drug: AZD4818 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD4818 300 mug twice daily
Trial: 16489477
Drug: Continuous passive
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous passive motion for 1 hour, twice a day, following total knee replacement surgery.
Trial: 8494127
Drug: Cimetidine 400
RxNorm normalized name: cimetidine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 400 mg, twice daily
Trial: 8494127
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg, twice daily
Trial: 30431725
Drug: Low-Level Laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-Level Laser Therapy (LLLT) switched off
Trial: 30431725
Drug: Low-Level Laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-Level Laser Therapy (LLLT) switched on
Trial: 26931110
Drug: Patient-controlled oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled oral analgesia
Trial: 26931110
Drug: Parenteral analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral analgesia
Trial: 17222352
Drug: Vehicle cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle cream (control group)
Trial: 9678143
Drug: Prostaglandin gel
RxNorm normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostaglandin gel with hygroscopic cervical dilators
Trial: 8008103
Drug: Patient point-of-view
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient point-of-view (PPOV1) delivery of regularly ordered medication by a pharmacy technician to the nurse server once a day
Trial: 8008103
Drug: Patient point-of-view
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient point-of-view (PPOV2) delivery of all medications (including stats and i.v.s) to the nurse server hourly between 0700 and 2300 hours
Trial: 8008103
Drug: Traditional medication
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional medication cart
Trial: 31763300
Drug: Topical mitomycin
RxNorm normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical mitomycin (0.4 mg/ml) applied for 5 min
Trial: 17724829
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy with prostamol Uno and tamsulosin
Trial: 17724829
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with prostamol Uno
Trial: 11391683
Drug: Bowman-Birk inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bowman-Birk inhibitor concentrate (BBIC)
Trial: 9521027
Drug: Compression therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compression therapy and treatment with HSE
Trial: 1092765
Drug: Purified type
RxNorm normalized name: collagen type I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purified type 1 M protein vaccine
Trial: 24127444
Drug: Intravenous arsenic
RxNorm normalized name: arsenic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous arsenic trioxide (ATO) 0.16 mg/kg
Trial: 24127444
Drug: Oral tetra-arsenic
RxNorm normalized name: Tetra-arsenic tetra-sulfide
DrugBank: Tetraarsenic tetrasulfide (DB19141)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tetra-arsenic tetra-sulfide (RIF) plus ATRA
Trial: 26403986
Drug: Intravenous arsenic
RxNorm normalized name: arsenic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous arsenic trioxide (ATO) plus ATRA
Trial: 12201825
Drug: Physiological dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiological dose (0.0017 mg/kg/day)
Trial: 12201825
Drug: Physiological dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiological dose (0.0033 mg/kg/day)
Trial: 12201825
Drug: Supraphysiological dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supraphysiological dose (0.010 mg/kg/day)
Trial: 12201825
Drug: Supraphysiological dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supraphysiological dose (0.025 mg/kg/day)
Trial: 12201825
Drug: Overall increase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall increase in GH dose
Trial: 7863248
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg nizatidine nocte (n = 86)
Trial: 7863248
Drug: 2 x
RxNorm normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 150 mg/d nizatidine (n = 93)
Trial: 7863248
Drug: nizatidine 150
RxNorm normalized name: nizatidine 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nizatidine 150 mg nocte (116 patients)
Trial: 7863248
Drug: 2 x
RxNorm normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 150 mg nizatidine daily (121 patients)
Trial: 782497
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose of beclomethasone dipropionate
Trial: 21334655
Drug: Finasteride 5
RxNorm normalized name: finasteride 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finasteride 5 mg alone
Trial: 25465944
Drug: Finasteride 5
RxNorm normalized name: finasteride 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finasteride 5 mg with Tamsulosin 0.2 mg
Trial: 19060462
Drug: Pimecrolimus cream
RxNorm normalized name: Pimecrolimus
DrugBank: Pimecrolimus (DB00337)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pimecrolimus cream plus colchicine tablets (1-2 g/day)
Trial: 19060462
Drug: Colchicine tablets
RxNorm normalized name: Colchicine Tablets
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colchicine tablets (1-2 g/day)
Trial: 14679365
Drug: Red Grape
RxNorm normalized name: CVS Children's Cold & Cough Elixir (Red Grape)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red Grape Juice (RGJ) 500 ml/day
Trial: 11179106
Drug: NO2 (10-μg/m3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NO2 (10-μg/m3 increment)
Trial: 11179106
Drug: TSP (10-μg/m3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TSP (10-μg/m3 increment)
Trial: 11179106
Drug: O3 (10-μg/m3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: O3 (10-μg/m3 increment)
Trial: 9215818
Drug: CMF (cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMF (cyclophosphamide 100 mg/m2 orally on days 1 to 14, methotrexate 40 mg/m2 intravenously on days 1 and 8, fluorouracil 600 mg/m2 intravenously on days 1 and 8)
Trial: 9215818
Drug: LMF (chlorambucil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LMF (chlorambucil 5 mg/m2 orally on days 1 to 14 with some I.V. cytostatic drugs)
Trial: 26826622
Drug: Sirolimus eluting
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus eluting stents (SES) in insulin-treated patients
Trial: 26826622
Drug: Paclitaxel eluting
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel eluting stents (PES) in insulin-treated patients
Trial: 23451852
Drug: Pimecrolimus 1%
RxNorm normalized name: PIMECROLIMUS 1% CREAM,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimecrolimus 1% cream applied twice daily for 2 months
Trial: 17944760
Drug: Supportive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive therapy intervention (n = 34)
Trial: 19032300
Drug: Ephedrine 10
RxNorm normalized name: pseudoephedrine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine 10 mg
Trial: 1449275
Drug: Retreatment with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retreatment with the same dose of ivermectin after six months
Trial: 30193556
Drug: 50% Concurrent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50% Concurrent and 100% Terminal (50% C & 100% T)
Trial: 30193556
Drug: 0% Concurrent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0% Concurrent and 100% Terminal (0% C & 100% T)
Trial: 30193556
Drug: 100% Concurrent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100% Concurrent and Terminal (100% C&T)
Trial: 27392045
Drug: Gluten (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gluten (20 g/day)
Trial: 24439191
Drug: Intravenous ceftazidime
RxNorm normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ceftazidime treatment
Trial: 24439191
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no prophylaxis of antibiotics)
Trial: 7612386
Drug: Plasmapheresis (PP)
RxNorm normalized name: propoxyphene hydrochloride Oral Capsule [PP-Cap]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasmapheresis (PP) therapy only
Trial: 7612386
Drug: Plasmapheresis (PP)
RxNorm normalized name: propoxyphene hydrochloride Oral Capsule [PP-Cap]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasmapheresis (PP) + high dose intravenous methylprednisolone therapy (pulse therapy)
Trial: 7612386
Drug: Repeated Plasmapheresis
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated Plasmapheresis (PP) + pulse therapy
Trial: 2198157
Drug: Pirazolac (300-600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirazolac (300-600 mg b.i.d.)
Trial: 2198157
Drug: Indomethacin (25-50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (25-50 mg t.i.d.)
Trial: 31537689
Drug: Conventional or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional or intensified chemotherapy
Trial: 26395866
Drug: MDMA (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDMA (125 mg orally)
Trial: 12975594
Drug: Orbiofan (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orbiofan (50 mg BID)
Trial: 9172027
Drug: Priming dose
RxNorm normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Priming dose of rocuronium 0.06 mg/kg followed two minutes later by an intubating dose of rocuronium 0.54 mg/kg
Trial: 3549843
Drug: Indomethacin, 100
RxNorm normalized name: Indomethacin, 100 mg rectal suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin, 100 mg per day
Trial: 28796588
Drug: G-CHOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CHOP
Trial: 15730413
Drug: High-dose rhGH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose rhGH (0.2 U/kg/day)
Trial: 15730413
Drug: Low-dose rhGH
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose rhGH (0.1 U/kg/day)
Trial: 10389710
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg PGE2 gel
Trial: 20027351
Drug: Ultralow doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultralow doses of antibodies to human IFN-gamma (anaferon pediatric formulation and anaferon)
Trial: 9677555
Drug: Peribulbar injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peribulbar injection (9 ml of anaesthetic from an inferotemporal site)
Trial: 9677555
Drug: Retrobulbar injection
RxNorm normalized name: LIDOCAINE HYDROCHLORIDE 40 mg in 1 mL RETROBULBAR INJECTION, SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retrobulbar injection (local anaesthetic through conjunctiva and facialis blockade)
Trial: 8303829
Drug: Kicking to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kicking to move a block mobile displaying horizontal and vertical lines (textons) arranged as L, T, or +
Trial: 2467588
Drug: Morphine 1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 1.8 mg iv every 8 min as required
Trial: 2467588
Drug: Meperidine 18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine 18 mg iv every 8 min as required
Trial: 2467588
Drug: Oxymorphone 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxymorphone 0.3 mg iv every 8 min as required
Trial: 28224442
Drug: SAP+PERT (Strength,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAP+PERT (Strength, Agility, and Secondary Prevention treatment plus Perturbation Training)
Trial: 8100911
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine given at induction of anaesthesia (iv pre)
Trial: 8100911
Drug: Intramuscular morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular morphine given 1 hour before operation (im pre)
Trial: 8100911
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine given at closure of the peritoneum (iv post)
Trial: 3520204
Drug: Cianidanol (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cianidanol (1.5 g daily for 2 weeks, then 2.25 g for 14 weeks)
Trial: 27883319
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of HRT and walking
Trial: 17396068
Drug: Nisoldipine coat-core
RxNorm normalized name: Nisoldipine
DrugBank: Nisoldipine (DB00401)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nisoldipine coat-core (CC)
Trial: 7604380
Drug: Total Parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total Parenteral Nutrition (TPN) in patients with sepsis
Trial: 7604380
Drug: Total Parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total Parenteral Nutrition (TPN) in ambulatory patients receiving HPN
Trial: 1970738
Drug: Bupivacaine-morphine mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine-morphine mixture (0.125% bupivacaine with morphine 0.05 mg kg‐1)
Trial: 1970738
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (Bupivacaine-morphine mixture and Bupivacaine alone)
Trial: 396690
Drug: amoxycillin 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amoxycillin 1.5 g daily
Trial: 396690
Drug: ampicillin 4
RxNorm normalized name: ampicillin 45 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ampicillin 4 g daily
Trial: 29799344
Drug: Ketamine (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (any dose)
Trial: 31486447
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg resveratrol per day
Trial: 19930904
Drug: Immunotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy with Ulinastatin plus Thymosin‐alpha(1)
Trial: 15917722
Drug: HESA‐A (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HESA‐A (50 mg/kg/day)
Trial: 12684572
Drug: Daily supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily supplementation with antioxidant vitamins and minerals at nutritional doses
Trial: 1817626
Drug: 0.375% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.375% bupivacaine 45 ml (168.75 mg) with adrenaline 1 in 200,000
Trial: 1817626
Drug: Plain solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain solution (bupivacaine without adrenaline)
Trial: 15257046
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of steroid-free versus steroids at 3 months
Trial: 15257046
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of steroid-free versus steroids at 12 months
Trial: 9525435
Drug: Cidofovir 3
RxNorm normalized name: cidofovir 375 MG in 5 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cidofovir 3 mg/kg once every other week
Trial: 9525435
Drug: Cidofovir therapy
RxNorm normalized name: Cidofovir
DrugBank: Cidofovir (DB00369)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cidofovir therapy
Trial: 7893034
Drug: Propofol (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (2.5 mg/kg) and vecuronium (0.15 mg/kg)
Trial: 17298428
Drug: Tacrolimus 0.03%
RxNorm normalized name: TACROLIMUS 0.03% OINT,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrolimus 0.03% ointment
Trial: 31668003
Drug: Tacrolimus 0.03%
RxNorm normalized name: TACROLIMUS 0.03% OINT,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrolimus 0.03% ointment and microdermabrasion
Trial: 22776634
Drug: Lurasidone 40
RxNorm normalized name: lurasidone 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurasidone 40 mg/d
Trial: 22776634
Drug: Lurasidone 80
RxNorm normalized name: lurasidone 80 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurasidone 80 mg/d
Trial: 30172595
Drug: Risperidone 4
RxNorm normalized name: risperidone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone 4 mg/d
Trial: 16715687
Drug: Short duration
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short duration regimen (60 mg per day tapered over 12 weeks)
Trial: 16715687
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose regimen (60 mg per day tapered over 20 weeks)
Trial: 11547070
Drug: Intrarectal instillation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrarectal instillation of 2% lidocaine gel
Trial: 9337437
Drug: Sequential intravenous‐to‐oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential intravenous‐to‐oral ofloxacin
Trial: 9337437
Drug: Standard intravenous‐to‐oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard intravenous‐to‐oral switch therapy
Trial: 9337437
Drug: Standard switch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard switch therapy
Trial: 7835811
Drug: Cisplatin (adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (adjuvant treatment)
Trial: 7835811
Drug: 32P (adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 32P (adjuvant treatment)